CAR-T Archives

News and Trends 17 Feb 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

These are the best results yet for CAR-T, this time from a research group led by Dirk Busch at the Technical University of Munich (Germany). In part backed by Juno Therapeutics, a method to select more potent T-cells and engineer a safety mechanism was announced at the annual meeting of the AAAS in Washington (US). CAR-T therapies are one of the ways […]

February 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Feb 2016

World CAR-T Leader Starts New Program with a UK Biotech

Pretty impressive CAR-T news coming from across the Channel… Oxford BioMedica just launched a second collaboration with Novartis, which has shown tremendous Phase II results – and the most advanced in CAR-T therapy in development so far (read our review on how CAR-T works and who else is working the field). This collaboration covers the […]

February 1, 2016 - 2 minutesmins - By Philip Hemme

News and Trends 26 Jan 2016

2011-2015: What a Fantastic 5 Years for European Biotech

The crisis of 2008 hit the Biotech sector hard, and it wasn’t clear how the Biotech industry would get back on track. But now, end of 2015, we can definitely say the Biotech industry did extremely well and probably better than most of the analysts would have predicted… So what were the major news stories […]

January 26, 2016 - 5 minutesmins - By Philip Hemme

News and Trends 12 Jan 2016

Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled

Cellectis researchers have managed to come up with a new CAR architecture with a small-molecule triggered ‘on-switch’, permitting better control and safety in CAR T-cell therapy, as published in Nature. As we discussed during our interview with Andre Choulika, CEO of Cellectis, last month, one major drawback to CAR-T treatment for cancer is the lack of […]

January 12, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Jan 2016

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

So it begins…dubbed the ‘Miracle Cure’ for Blood Cancer, UCART19 is now set to begin its journey to Human trials in the UK. Just 2 days before Christmas, the French billion euro Biotech, Cellectis, submitted a clinical trial application to the Medicines & Healthcare products Regulatory Agency (MHRA). Specifically, the request was to approve initiation […]

January 4, 2016 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Dec 2015

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Wow! 55 of 59 patients in a Novartis trial experienced complete remission in one of the largest investigational CAR-T therapies for children with relapsed/refractory acute lymphoblastic leukemia (ALL). These are the latest findings from an ongoing phase II study of CTL019, an investigational chimeric antigen receptor T-cell (CAR-T) therapy, further support its potential in the […]

December 9, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 30 Nov 2015

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

CAR-T is solidifying in everybody’s mind as the next revolution in Cancer treatment. But there is still a lot to do…That’s basically what came out from my discussion with André Choulika, the CEO of the French CAR-T miracle Cellectis. Cellectis is probably the most successful Biotech in France. It was founded in 1999 by Choulika […]

November 30, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis’s leading product UCART19 for blood cancer. This unusual move only further feeds the rumours of Pfizer’s potential future acquisition of Cellectis. As we’ve discussed before, Cellectis has moved most […]

November 19, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 19 Nov 2015

“The Next Generation of Biologicals will be Cell-based”

That’s what Zami Aberman, CEO of one of the world-leading cell-therapy company Pluristem told me during our lunch at Berlin this week. An enthusiastic statement for a sector that could indeed be the next blockbuster after the monoclonal antibodies. Pluristem is an Israel based Biotech company developing off-the-shelf cell therapies for a variety of human diseases. What makes […]

November 19, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 9 Nov 2015

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

Cell-based Immune-oncology therapies continue to deliver amazing results. After Cellectis wondersaving from last week, Oxford’s Adaptimmune has some surprisingly good results too. Adaptimmune is a British, Oxford-based immuno-oncolgy company. It held a massive IPO last year, raising up to €150M on the NASDAQ, and its CEO was interviewed by BIO (video here) where he seemed […]

November 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 7 Nov 2015

What Happened this Week? BIO-Europe 2015, mRNA deal, Cellectis CAR-T

Monday: The French Scientist Who Also ‘Discovered’ CRISPR is Finally Recognized with a Prize too Tuesday: €100 Million Investment Round Prepares CureVac For Vaccine Expansion Wednesday: €1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech Thursday: Damn, that was BIO-Europe 2015 in Munich! Friday: Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on […]

November 7, 2015 - 1 minutemin - By Philip Hemme

News and Trends 6 Nov 2015

Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?

About 30%. That’s how Cellectis‘ NASDAQ stock price has jumped between the 4th and the 5th of November. But why? Basically, because of the first human success of their allogeneic CAR-T therapy! The Great Ormond Street Hospital (UK) treated a young patient with refractory relapsed Acute Lymphoblastic Leukemia (ALL) with Cellectis’ allogeneic UCART19 product candidate in June. To […]

November 6, 2015 - 2 minutesmins - By Jerome Topsent

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

CAR-T

Cancer: World Best Ever CAR-T Results have Just been Disclosed

World CAR-T Leader Starts New Program with a UK Biotech

2011-2015: What a Fantastic 5 Years for European Biotech

Cellectis has Discovered an ‘On-Switch’ to Make CAR-T Safer and Better Controlled

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

CAR-T Phase II: 93% Complete Remission in Children with Relapsed Leukemia!

Cellectis’ CEO: “I’m just trying to be realistic, CAR-T is not THE miracle cure for Cancer”

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

“The Next Generation of Biologicals will be Cell-based”

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

What Happened this Week? BIO-Europe 2015, mRNA deal, Cellectis CAR-T

Cellectis’ Miraculous Saving of a Baby Girl. What’s the impact on the CAR-T field?

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!